Enables DNA-binding transcription factor activity; protein kinase binding activity; and sequence-specific DNA binding activity. Involved in several processes, including cellular response to glucose stimulus; fatty acid homeostasis; and regulation of nucleobase-containing compound metabolic process. Located in cytosol and nucleus. Biomarker of end stage renal disease; kidney disease; metabolic dysfunction-associated steatohepatitis; metabolic dysfunction-associated steatotic liver disease; and type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in coronary artery disease and myocardial infarction. Orthologous to human MLXIPL (MLX interacting protein like); PARTICIPATES IN glycolysis/gluconeogenesis pathway; INTERACTS WITH (+)-schisandrin B; 17beta-estradiol; 6-propyl-2-thiouracil.
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[Tetrachlorodibenzodioxin co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] results in decreased expression of MLXIPL mRNA
Dietary Fats promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of MLXIPL mRNA] and Tetrachlorodibenzodioxin inhibits the reaction [Dietary Fats results in increased expression of MLXIPL mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MLXIPL mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of MLXIPL mRNA
[Glucose co-treated with S 4048] results in increased expression of MLXIPL mRNA and Glucose promotes the reaction [MLXIPL protein binds to TUG1 promoter]
[Bexarotene co-treated with GW 3965] results in decreased expression of MLXIPL mRNA and [Bexarotene co-treated with T0901317] results in decreased expression of MLXIPL mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MLXIPL mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MLXIPL mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA and Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA]
[Glucose co-treated with S 4048] results in increased expression of MLXIPL mRNA and Glucose promotes the reaction [MLXIPL protein binds to TUG1 promoter]
[ANGPTL4 gene mutant form results in increased susceptibility to Dexamethasone] which results in decreased expression of MLXIPL mRNA and ANGPTL4 gene mutant form inhibits the reaction [Dexamethasone results in decreased expression of MLXIPL mRNA alternative form]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MLXIPL mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of MLXIPL mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MLXIPL mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MLXIPL mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MLXIPL mRNA
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with diisononyl phthalate co-treated with Dibutyl Phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] affects the expression of MLXIPL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLXIPL mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLXIPL mRNA
[difenoconazole co-treated with fludioxonil] results in decreased expression of MLXIPL mRNA and [tebuconazole co-treated with fludioxonil] results in decreased expression of MLXIPL mRNA
[Glucose co-treated with S 4048] results in increased expression of MLXIPL mRNA and Glucose promotes the reaction [MLXIPL protein binds to TUG1 promoter]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of MLXIPL mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of MLXIPL mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin inhibits the reaction [Fructose results in increased activity of MLXIPL protein]]
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MLXIPL mRNA
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA and Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA]
[propiconazole co-treated with tebuconazole] results in increased expression of MLXIPL mRNA and [tebuconazole co-treated with fludioxonil] results in decreased expression of MLXIPL mRNA
[Caffeine co-treated with coclaurine co-treated with aegeline co-treated with higenamine co-treated with Yohimbine co-treated with Hydrolyzable Tannins] results in increased expression of MLXIPL mRNA
Coordinate regulation/localization of the carbohydrate responsive binding protein (ChREBP) by two nuclear export signal sites: discovery of a new leucine-rich nuclear export signal site.
Fasting for 3 days during the suckling-weaning transient period in male rats induces metabolic abnormalities in the liver and is associated with impaired glucose tolerance in adulthood.
Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase.
Amino acid change in the carbohydrate response element binding protein is associated with lower triglycerides and myocardial infarction incidence depending on level of adherence to the Mediterranean diet in the PREDIMED trial.
Effect of Creosote Bush-Derived NDGA on Expression of Genes Involved in Lipid Metabolism in Liver of High-Fructose Fed Rats: Relevance to NDGA Amelioration of Hypertriglyceridemia and Hepatic Steatosis.